Defective i⁶A37 Modification of Mitochondrial and Cytosolic tRNAs Results from Pathogenic Mutations in TRIT1 and Its Substrate tRNA by Yarham, John W. et al.
Defective i6A37 Modification of Mitochondrial and
Cytosolic tRNAs Results from Pathogenic Mutations in
TRIT1 and Its Substrate tRNA
John W. Yarham1., Tek N. Lamichhane2., Angela Pyle3, Sandy Mattijssen2, Enrico Baruffini4,
Francesco Bruni1, Claudia Donnini4, Alex Vassilev2, Langping He1, Emma L. Blakely1, Helen Griffin3,
Mauro Santibanez-Koref3, Laurence A. Bindoff5,6, Ileana Ferrero4, Patrick F. Chinnery3,
Robert McFarland1, Richard J. Maraia2*, Robert W. Taylor1*
1Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, The Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom,
2 Intramural Research Program, NICHD, NIH, Bethesda, Maryland, United States of America, 3Wellcome Trust Centre for Mitochondrial Research, Institute for Genetic
Medicine, The Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom, 4Department of Life Sciences, University of Parma, Parma, Italy,
5Department of Neurology, Haukeland University Hospital, Bergen, Norway, 6Department of Clinical Medicine, University of Bergen, Bergen, Norway
Abstract
Identifying the genetic basis for mitochondrial diseases is technically challenging given the size of the mitochondrial
proteome and the heterogeneity of disease presentations. Using next-generation exome sequencing, we identified in a
patient with severe combined mitochondrial respiratory chain defects and corresponding perturbation in mitochondrial
protein synthesis, a homozygous p.Arg323Gln mutation in TRIT1. This gene encodes human tRNA isopentenyltransferase,
which is responsible for i6A37 modification of the anticodon loops of a small subset of cytosolic and mitochondrial tRNAs.
Deficiency of i6A37 was previously shown in yeast to decrease translational efficiency and fidelity in a codon-specific
manner. Modelling of the p.Arg323Gln mutation on the co-crystal structure of the homologous yeast isopentenyltransferase
bound to a substrate tRNA, indicates that it is one of a series of adjacent basic side chains that interact with the tRNA
backbone of the anticodon stem, somewhat removed from the catalytic center. We show that patient cells bearing the
p.Arg323Gln TRIT1 mutation are severely deficient in i6A37 in both cytosolic and mitochondrial tRNAs. Complete
complementation of the i6A37 deficiency of both cytosolic and mitochondrial tRNAs was achieved by transduction of
patient fibroblasts with wild-type TRIT1. Moreover, we show that a previously-reported pathogenic m.7480A.G mt-
tRNASer(UCN) mutation in the anticodon loop sequence A36A37A38 recognised by TRIT1 causes a loss of i6A37 modification.
These data demonstrate that deficiencies of i6A37 tRNA modification should be considered a potential mechanism of
human disease caused by both nuclear gene and mitochondrial DNA mutations while providing insight into the structure
and function of TRIT1 in the modification of cytosolic and mitochondrial tRNAs.
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Introduction
Mitochondrial diseases are characterised by biochemical defects
in oxidative phosphorylation (OXPHOS) enzyme activity and
arise as a consequence of nuclear- or mitochondrial-encoded gene
mutations [1]. Generalised disorders of mitochondrial protein
synthesis resulting in OXPHOS defects are increasingly reported
as causing a clinically heterogeneous group of neonatal and
infantile mitochondrial disease presentations associated with
isolated or multi-organ involvement [2]. The advent of whole
exome capture and sequencing technologies has revolutionised the
molecular diagnosis of this patient group [3]; the molecular disease
mechanism can implicate nuclear gene products involved in
mitochondrial DNA (mtDNA) replication, synthesis and repair [4],
mitochondrial aminoacyl tRNA synthetases [5], mitochondrial
translation elongation and release factors [6], structural ribosomal
proteins and assembly factors, and enzymes involved in mt-RNA
modification [7].
Post-transcriptional modification of tRNAs is crucial for folding,
stability and function in deciphering the genetic code during
translation. Modifications of cytosolic-tRNAs (cy-tRNA) and mt-
tRNAs occur notably at nucleotide positions 34 and 37 in the
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anticodon loop (ACL), serving to promote translational fidelity and
efficiency by optimising codon-anticodon fit within the ribosome
[8]. The homologous tRNA isopentenyltransferases (IPTases) are
conserved from bacteria to humans and introduce an evolution-
arily ancient modification, an isopentenyl group onto N6 of
adenine at position 37 (i6A37). In bacteria, i6A37 is further
modified by methylthiolation to ms2i6A37 which uses its methyl-
sulphur group to stabilise the intrinsically weak A–U pairing
between anticodon A36 and the first base of UNN codons [9].
However, the methylthiolation enzymes are not present in
eukaryotes, leaving i6A37 without further modification.
To date, functional analysis in eukaryotes comes from studies in
yeast which have shown that i6A37 promotes translational
efficiency and fidelity in a codon-specific manner cognate with
the i6A37-tRNAs [10]. The presence of i6A37 increases the
specific activity of a tRNA for its codon about four-fold in S. pombe
[10]. Prior work on orthologues including MiaA (E. coli), Tit1 (S.
pombe), Mod5 (S. cerevisiae), and TRIT1 (human) has revealed
specificity for subsets of cy- and mt-tRNAs that bear the single-
stranded anticodon loop recognition sequence, ‘A36-A37-A38’,
although this motif alone is not always sufficient ([11] and refs
therein). However, it has also become clear that due to sequence
variability in the tRNAs and the specificities of the transferases,
different species contain different subsets of i6A37-modified tRNAs
[10,12]. Determining the subsets of specific mRNAs that are
sensitive to i6A37 deficiency and how this contributes to phenotype
is a contemporary challenge [10].
We used whole exome sequencing to identify a homozygous
p.Arg323Gln mutation in the TRIT1 gene that segregates within a
consanguineous UK-Pakistani family in which affected children
present with encephalopathy and myoclonic epilepsy due to
multiple OXPHOS deficiencies in skeletal muscle. We confirm
that this mutation is responsible for a severe deficiency in the
i6A37 content of cy- and mt-tRNAs, as it can be reversed by rescue
with wild type TRIT1 in the patient’s fibroblasts. We show that
TRIT1 is targeted to mitochondria and provide evidence in both
humans and yeast that this gene is required for efficient
mitochondrial function. Furthermore, we have demonstrated
that a previously-reported pathogenic A38G mutation of mt-
tRNASer(UCN), causes i6A37 deficiency, strengthening the conclu-
sion that TRIT1-related human disease can arise from mutation of
either the enzyme or its tRNA substrate.
Results
Histochemical and biochemical analyses identified a
generalised disorder of mitochondrial protein synthesis
We investigated a family with clinical indications of mitochon-
drial disease in two affected children. A skeletal muscle biopsy
(subject II-3, detailed clinical report in Text S1) showed normal
morphology and a mosaic pattern of cytochrome c oxidase (COX)
deficiency (Figure 1A), which can be associated with mutations in
nuclear genes involved with mtDNA translation and maintenance
or mtDNA mutations. We also observed biochemical evidence of a
mitochondrial respiratory chain deficiency involving complexes I
(10% of controls) and IV (60% of controls), with apparent sparing
of complex II and III activity (Figure 1B). Together these data
confirmed the presence of a combined OXPHOS deficiency.
Micro-scale oxygraphy analysis provided evidence of mitochon-
drial respiratory dysfunction in patient fibroblasts (Figure 1C and
D). Basal oxygen consumption rate (OCR) was significantly
decreased (P= 0.0451) in the patient compared to controls, as was
maximal OCR (P= 0.0078). The spare respiratory capacity (SRC)
(Figure 1C) was significantly reduced (P= 0.0102) in patient cells
whilst the coupling efficiency of ATP synthesis to respiration, a
measure of proton leak, was unchanged (Figure 1D).
In vitro metabolic labelling of mitochondrial translation identi-
fied a generalised decrease in the synthesis of mtDNA-encoded
proteins with particularly notable loss of ND1 and ND5 of
Complex I, CYTB of Complex III and COXI, COXII and
COXIII of Complex IV (Figure 1E). This was supported by
immunoblotting, which revealed decreased steady-state levels of
mtDNA-encoded OXPHOS components in the patient fibroblasts
(Figure 1F) and a moderate decrease in SDHA protein levels
which was surprising given that complex II activity in skeletal
muscle was normal (Figure 1F). Levels of TOMM20 were
unchanged in patient cells confirming a specific defect of
OXPHOS protein synthesis rather than general loss of mitochon-
drial proteins.
Exome sequencing identified a mutation in TRIT1
Having excluded mtDNA rearrangements, copy number
abnormalities and point mutations (Table S1), we employed
whole exome sequencing of both affected siblings to elucidate a
potential genetic basis of the defect. This analysis identified 3970
novel homozygous protein altering variants shared between
siblings (Table S2), of which 40 were rare (Minor Allele Frequency
,0.01). Based on predicted mitochondrial localisation and an
autosomal recessive inheritance pattern, variant filtering identified
a single candidate homozygous missense mutation shared by both
affected siblings in TRIT1 (c.968G.A predicting p.Arg323Gln).
This mutation was predicted to be pathogenic by PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/) with a score of 0.999.
Targeted resequencing of the proband and familial relatives
confirmed the homozygous mutation in the affected siblings and
demonstrated disease segregation as both parents and an
unaffected sibling were heterozygous carriers (Figure 2A). Impor-
tantly, the TRIT1 c.968G.A variant was not observed by the
1000 Genomes Project, the NHLBI Exome Sequencing Project
nor a panel of 120 ethnically-matched control chromosomes (data
not shown).
Author Summary
Mitochondrial disorders are clinically diverse, and identify-
ing the underlying genetic mutations is technically
challenging due to the large number of mitochondrial
proteins. Using high-throughput sequencing technology,
we identified a disease-causing mutation in the TRIT1
gene. This gene encodes an enzyme, tRNA isopentenyl-
transferase, that adds an N6-isopentenyl modification to
adenosine-37 (i6A37) in a small number of tRNAs, enabling
them to function correctly during the synthesis of essential
mitochondrial proteins. We show that this mutation leads
to severe deficiency of tRNA-i6A37 in the patient’s cells
that can be rescued by introduction of the wild-type TRIT1
protein. A deficiency in oxidative phosphorylation, the
process by which energy (ATP) is generated in the
mitochondria, leads to a mitochondrial disease presenta-
tion. Introducing the mutant protein into model yeast
species and measuring the resulting impairment provided
further evidence of the pathogenic effect of the mutation.
Additional studies investigating a previously reported
pathogenic mutation in a mitochondrial tRNA gene
demonstrated that a mutation in a substrate of TRIT1
can also cause a loss of the modification, providing
evidence of a new mechanism causing mitochondrial
disease in humans.
Defective i6a Modification of tRNAs Causes Disease
PLOS Genetics | www.plosgenetics.org 2 June 2014 | Volume 10 | Issue 6 | e1004424
The p.Arg323Gln mutation occurs in exon 8 of the TRIT1
gene, which also has a putative mitochondrial targeting sequence
in exon 1 and a matrin-type zinc finger domain contributed by
exons 10 and 11 (Figure 2B). Mitochondrial targeting of TRIT1 is
supported by prediction using the freely available online tool,
MitoProt II (http://ihg.gsf.de/ihg/mitoprot.html) [13], with a
confidence of 94%. Both cytosolic and mitochondrial localization
is predicted by other available databases, as is also the case for its
homologs Mod5, Tit1, and GRO-1. Indeed, immunoblotting of
whole cell extracts and isolated mitochondrial subfractions
confirmed that TRIT1 was present in the cytosolic fraction
(Figure 2C, lane 2) and also detectable in proteinase K-treated
mitoplasts (lane 6), consistent with the enzyme being present in the
mitochondrial matrix, where tRNA molecules and the translation
apparatus are active during protein synthesis. However, at this
stage we cannot exclude the possibility that a significant fraction of
the cytosolic portion of TRIT1 may be associated with the outer
mitochondrial membrane.
The corresponding position of the affected amino acid,
p.Arg323, is occupied by a basic side chain in all homologues
from a range of species (Figure 2D), whereas glutamine at this
position in the proband is polar but uncharged. Based on the
available Mod5-tRNA co-crystal structure [14] (Figure 2E–G), the
position and chemical nature of the mutation was not expected to
affect mitochondrial localization, general solubility or gross
structural alterations of the enzyme. In Mod5 this position is
occupied by p.Lys294 whose basic side chain extends from an
a-helix that lies adjacent to, but pointing away from, the catalytic
site containing A37 [14]. Both this and adjacent conserved basic
side chains comprise part of a series of residues on the same side of
the a-helix, including Arg298 (also arginine in TRIT1) which are
involved in binding the phosphate groups of nucleotides 27–29 of
the AC stem (Figure 2E–G) [14]. Based on this we suspected that
the mutation would not impair catalytic activity per se but might
impair proper binding of the enzyme to its tRNA substrates.
However, since this mutation would appear to affect only one of a
series of contacts with the surface of the tRNA backbone, it was
not necessarily expected to cause a severe deficiency of
isopentenyltransferase activity.
The TRIT1 p.Arg323Gln mutation severely impairs i6A
modification activity
Purified recombinant TRIT1 was previously used to examine
i6A modification activity in vitro using an established assay
employing synthetic RNA that matches the anticodon stem loop
(ASL) of a substrate tRNA [11]. By this assay, the isopentenyl
group of DMAPP (dimethylallyl pyrophosphate) is transferred to
N6 of A37 in substrate tRNAs by the IPTase TRIT1 ([11] and
references therein). His-tagged TRIT1-WT and His-tagged
TRIT1-Arg323Gln were purified from E. coli in parallel and
compared by gel electrophoresis (Figure 3A). The modification
activity of mutant TRIT1 was negligible relative to that of wild-
type TRIT1 using the standard assay (Figure 3B). We reasoned
that if the mutation led to decreased affinity for its substrate, as
suggested by the co-crystal structure of Mod5-tRNA, we might be
able to obtain activity by increasing substrate concentration. Some
activity of mutant TRIT1 could indeed be observed by increasing
the concentration of the RNA substrate 4-fold, but even under
these conditions it was much less active than the wild-type TRIT1
(Figure 3C). Although increasing the concentrations of enzyme
and substrate further was technically-limited in these reactions, the
data suggest that higher activity might be achieved with higher
concentrations.
Mutant TRIT1 fails to complement activity of a codon-
specific cytoplasmic translational reporter or a
mitochondrial respiratory growth defect in a tit1-
knockout strain of S. pombe
A previously characterized S. pombe strain with a deletion of the
tit1+ gene (a homologue of TRIT1), yNB5, exhibits two distinct
phenotypes [10,11] that were examined for their sensitivity to
wild-type TRIT1 and the p.Arg323Gln TRIT1 mutant. The first
phenotype is manifested by a red-white colony colour assay, that
monitors tRNASer(UCA)-mediated suppression of a UGA nonsense
mutation in ade6-704. This in vivo assay reports on the codon-
specific translational activity of the suppressor-tRNASer(UCA) to
decode the ade6-704 UGA codon, which was previously shown to
be highly dependent on i6A37 [10,11]. In this assay, absence of
i6A37 decreases the translational activity of the suppressor-tRNA
and the cells accumulate red pigment [11]. The yNB5 strain
(tit1-D) transformed with the empty vector is red as expected,
whilst the yYH1 strain (tit1+) is white. yNB5 transformed with
either wild-type TRIT1 or wild-type tit1+ are white, indicating
successful complementation, whilst yNB5 transformed with
mutant TRIT1 is red (Figure 3D).
The second phenotype of the yNB5 strain is slow growth in
glycerol, which is a manifestation of mitochondrial respiratory
dysfunction. This growth defect could be rescued by tit1+ but not
by a catalytically debilitated mutant-tit1 carrying a point
mutation [10]. The positive control, yYH1 (tit1+), grows well
when transformed with an empty vector, but yNB5 transformed
with an empty vector grows relatively poorly on glycerol.
Transformation with wild-type tit1+ or wild-type TRIT1 rescued
the growth defect of yNB5. However, whilst growth on glycerol
after transformation with the mutant TRIT1 was slightly better
than with the empty vector, rescue was less complete compared to
wild-type TRIT1 (Figure 3E). This partial rescue may reflect a
low level of i6A37 modification activity by the mutant TRIT1
enzyme.
Modelling of the mutation in S. cerevisiae demonstrates a
respiratory deficiency
We also generated a strain of S. cerevisiae with knock-out MOD5
(a homologue of TRIT1) which was transformed with either wild-
type MOD5, an empty vector, mod5K294R (humanised MOD5,
which carries the Lys294Arg mutation) or mod5K294Q (mutant
MOD5, which carries the Lys294Gln mutation). As observed in S.
pombe, mod5-D yeast transformed with mutant MOD5 showed a
reduced growth rate in a oxidative carbon source such as ethanol
compared to mod5-D yeast transformed with either wild-type
MOD5 or humanised MOD5 (Figure S1A). Oxidative growth
defects were due to reduced respiratory activity since mod5-D strain
transformed with an empty vector showed a significantly
decreased respiration rate (P = 0.0002) in comparison to yeast
transformed with wild-type MOD5, whilst mutant MOD5 failed to
rescue the respiration rate of the transformed yeast as efficiently as
wild-type or humanised MOD5 (Figure S1B).
The i6A37 modification is severely decreased in tRNAs
from patient-derived fibroblasts carrying the
p.Arg323Gln mutation
Immunoblotting of TRIT1 in fibroblasts from the proband
demonstrated no significant loss of protein levels in comparison to
control fibroblasts, using b-actin as a loading control (Figure 4A).
A second, smaller band that was barely detectable in the control
cell extract but more abundant in the patient cell extract was not
always reproducible, likely reflecting nonspecific protein degrada-
Defective i6a Modification of tRNAs Causes Disease
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Figure 1. Identification of a mitochondrial respiratory chain deficiency and defective mtDNA translation. A) Cytochrome c oxidase
(COX) histochemical reactivity revealed a mosaic of COX-deficiency in patient skeletal muscle compared to control. B) The assessment of individual
respiratory chain enzyme activities identified a combined OXPHOS deficiency affecting complexes I and IV in skeletal muscle from the proband. The
mean activity measured in 25 controls was set at 100%. C) Patient fibroblasts (grey) are less capable of responding to stress in comparison to control
fibroblasts (black), as measured by the spare respiratory capacity. *: P,0.05. D) The coupling efficiency of ATP synthesis and respiration, and therefore
the level of proton leak, is not decreased in patient fibroblasts (grey) compared to controls (black). The error bars displayed on each graph indicate
standard deviation. E) In vitro metabolic labelling of mitochondrial translation in patient fibroblasts (P) showed a generalised decrease in translation
activity, with the subunits of Complex I (notably ND5) and Complex IV (notably COXI) most substantially decreased. Even loading was confirmed by
Coomassie blue staining (CBS). F) Immunoblotting demonstrated a generalised decrease in the level of individual subunits from respiratory chain
complexes I–V (normalised to b-actin) in patient fibroblasts, whilst the mitochondrial marker, TOMM20 was unchanged.
doi:10.1371/journal.pgen.1004424.g001
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tion. Notably, our evidence indicates that mitochondrial TRIT1 is
the same molecular weight as the major band observed in the
extracts (see Figure 2C). We next examined the in vivo levels of
mitochondrial and cytosolic tRNA-i6A37 in patient and control
fibroblasts using the Positive Hybridisation in the Absence of i6A
(PHA6) assay [11]. As described previously, in the PHA6 assay,
strong binding of the ACL probe occurs only in the absence of
i6A37, whilst body probes (BP) efficiently bind the tRNA whether
or not i6A37 is present and were used to indicate relative levels of
the tRNAs [11]. Equal loading of the RNA was confirmed by
ethidium bromide imaging of the gel (Figure 4B, upper panel) and
by hybridization with appropriate BPs.
Both cy-tRNASer(UGA) and mt-tRNASer(UCN) had considerably
decreased i6A37 modification in patient fibroblasts compared to
control. In contrast, there was no difference in the ACL probing of
mt-tRNACys, which does have a A36A37A38 target site for
TRIT1 but is not modified, consistent with previous results [12].
The cy-tRNASer(UGA) appears to be fully modified in control
fibroblasts (undetectable with ACL probe) consistent with prior
results using HeLa cells [12] but largely unmodified in patient
fibroblasts (Figure 4B). The mt-tRNASer(UCN) shows a significant,
albeit decreased difference in the ACL signal between control and
patient compare to cy-tRNASer(UGA). This is due in part to a
significant fraction of unmodified mt-tRNASer(UCN) in the control
cells, again consistent with prior results using HeLa cells [12]. This
suggests that wild-type TRIT1 is only partially active on mt-
tRNASer(UCN) in control fibroblasts. The more similar mt-
tRNASer(UCN) ACL signals in control and patient fibroblasts is
also due in part to a significantly lower amount of the overall level
of mt-tRNASer(UCN) in the patient, as revealed by the mt-
tRNASer(UCN) BP. We note that whilst cy-tRNASer(UGA) showed
similar steady-state levels in control and patient cells, the mt-
tRNASer(UCN) showed a 40% decrease in steady-state level
(Figure 4B, quantification not shown but see Figure 5E), calculated
Figure 2. A TRIT1mutation segregates with disease and disrupts a conserved tRNA-binding basic side-chain. A) Targeted resequencing
of TRIT1 confirmed that the proband (II-3; arrow), and his clinically affected sister (II–1) are homozygous for the c.968G.A TRIT1 mutation, while his
unaffected older brother (II–2) and both of his parents (I–1 and I–2) are heterozygous carriers. B) The TRIT1 mutation is located in exon 8, whilst there
is a putative mitochondrial targeting sequence in exon 1 and a matrin-type zinc finger domain spanning exons 10 and 11. C) The mitochondrial sub-
localisation of TRIT1 is demonstrated by sub-fractionation and immunoblotting, using markers for each sub-fraction to confirm there was no
contamination: TOMM20 (mitochondrial outer membrane), AIF (mitochondrial intermembrane space), GDH (mitochondrial matrix), NDUFA9
(mitochondrial inner membrane) and eIF4E (cytosol). TRIT1 localized with eIF4E in the cytosol (lane 2) and showed the same profile as GDH (lanes 3–
6), but was undetectable in the inner mitochondrial membrane fraction (lane 7). A total of 40 mg protein was loaded for each sample, and all
mitochondrial subfractions were prepared from the same mitochondrial lysate. D) Clustal Omega alignment of the TRIT1 protein and known
orthologs revealed that the affected amino acid (p.Arg323) is conserved in each species excluding S. pombe, S. cerevisiae and E. coli, where the
equivalent amino acid is lysine, which has similar electrochemical properties (:). Asterisks (*) indicate completely conserved residues. E–G) The co-
crystal structure of Mod5 bound to a substrate tRNA (based on [14]) shows the interaction of the tRNA backbone (nucleotides 27–29) with an
extended a-helix in which are located multiple basic side chains (indicated in red) of the enzyme including that corresponding to the mutated
position (Lys294).
doi:10.1371/journal.pgen.1004424.g002
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using the BPs of mt-tRNASer(UCN) and mt-tRNACys as internal
calibration standards [10].
Wild-type TRIT1 rescues the i6A modification in patient
fibroblasts
Attempts to rescue the i6A37 hypomodification observed in
patient fibroblasts were met with significant technical challenges
that produced variable levels of transient transfection efficiency
and ectopic TRIT1 and therefore only partial rescue of the i6A37
hypomodification (data not shown). We therefore used a retrovirus
vector-based transduction approach to optimize the percentage of
cells expressing ectopic TRIT1. Transduction of control and
patient fibroblasts resulted in very high levels of overexpression as
compared to the empty vector (Figure 5A), allowing us to examine
the i6A37 content of tRNAs from patient cells (Figure 5B).
Importantly, wild-type TRIT1 completely reversed the cy-
tRNASer(UGA) hypomodification defect in the patient cells, whereas
the empty vector did not, providing strong evidence that the native
endogenous mutant TRIT1 protein is responsible for the
hypomodification (Figure 5B, compare lanes 7 & 8 with 9 & 10).
Given the very high overexpression of TRIT1 in these cells
(Figure 5A), it was not surprising based on our mutation structure
analysis, in vitro modification results and partial rescue of slow
growth in glycerol by the mutant TRIT1 protein, that mutant
TRIT1 was no less efficacious than wild-type TRIT1 in rescuing
the i6A37 hypomodification of cy-tRNASer(UGA) in patient cells
(Figure 5B).
In notable contrast to the rescue of cy-tRNASer(UGA) hypomo-
dification, the hypomodification of mt-tRNASer(UCN) was rescued
more efficiently by wild-type TRIT1 than mutant TRIT1
(Figure 5B). Moreover, restoration of i6A37 to mt-tRNASer(UCN)
was specifically associated with an overall increase in the steady
Figure 3. Mutant TRIT1 has decreased in vitro activity and cannot complement tit1-D defects in S. pombe. A) A Coomassie-blue stained
SDS polyacrylamide gel confirmed the parallel purification of His-tagged TRIT1-WT and His-tagged TRIT1-Mut from E. coli. B) Loss of the
isopentenyltransferase activity of TRIT1 carrying the p.Arg323Gln mutation was demonstrated by an in vitro assay using varying concentrations (nM)
of His-tagged TRIT1-WT and TRIT1-Mut as well as a standard amount of RNA substrate (2.5 mM) [11]. C) Mutant TRIT1 activity was shown to be very
low rather than absent by repeating the assay using 10 mM RNA and 400 nM of protein. D) Wild-type (yYH1) and tit1-D (yNB5) strains of the fission
yeast Schizosaccharomyces pombe were transformed with an empty vector (+V), the S. pombe tRNA isopentenyltransferase (+tit1+), wild-type human
TRIT1 (+TRIT1-WT) or mutant human TRIT1 (+TRIT1-Mut) and plated onto media containing limited adenine to assay for the loss of function of
tRNASer(UCA) due to lack of isopentenyl modification. tit1-deleted yeast carrying the empty vector or mutant TRIT1 showed no recovery of tRNASer(UCA)
function (red colonies), but knock-down yeast carrying wild-type TRIT1 or tit1+ showed recovery of tRNASer(UCA) activity (white colonies) similar to
wild-type yeast. E) Transformation of tit1-D yeast with wild-type TRIT1 or tit1+, but not the empty vector or mutant TRIT1, could also complement the
respiratory deficiency illustrated by slow growth on glycerol compared to growth on glucose; spots reflect 10-fold serial dilutions of the same
amounts of cells as determined by OD600.
doi:10.1371/journal.pgen.1004424.g003
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state levels of this tRNA as reflected by the mt-tRNASer(UCN) BP
(Figure 5B; compare lanes 7 and 8 with 9 and 10). Quantification
of independent triplicate sample sets revealed that whilst wild-type
TRIT1 could effectively recover the i6A37 modification level of
mt-tRNASer(UCN) to that observed in the control fibroblasts,,60%
(P=0.6286), mutant TRIT1 was significantly less efficient, at
,20% (P= 0.0146) (Figure 5C).
Wild-type TRIT1 promotes accumulation of mt-
tRNASer(UCN)
Using U5 snRNA as a loading control and mt-tRNACys and mt-
tRNALeu(UUR) as non-substrate mitochondrial controls, the steady-
state levels of both cy-tRNASer(UGA) (Figure 5D) and mt-
tRNASer(UCN) (Figure 5E) (calculated using BPs) in transduced
fibroblasts were determined. Curiously, cy-tRNASer(UGA) levels
relative to U5 RNA were reproducibly found to be significantly
higher in patient fibroblasts as compared to the control cells,
regardless of whether the transducing vector encoded TRIT1 or
not (Figure 5D). However, mt-tRNASer(UCN) levels, which were
relatively lower in patient fibroblasts, were more efficiently rescued
by wild-type TRIT1 (elevated relative to U5: P= 0.0162) than by
mutant TRIT1 (unchanged relative to U5: P= 0.2038) or the
empty vector (decreased relative to U5: P= 0.0055) when
compared to control fibroblasts transduced with empty vector
(Figure 5E, black bars). This quantitative trend was more
significant when calibrating the mt-tRNASer(UCN) levels relative
to the non-substrate control, mt-tRNACys in the patient cells
(Figure 5E, grey bars).
We tried various approaches to rescue the biochemical,
respiratory and molecular phenotypes in the patient fibroblasts.
However due to limitations associated with the manipulation and
transfection of patient and control fibroblasts, we were unable to
do so with either wild-type or mutant TRIT1 despite multiple
attempts (not shown). It appears that the cells had become less
dependent on and/or less expressive of respiratory function with
passage and handling.
Figure 4. The TRIT1mutation disrupts modification activity on cytosolic and mitochondrial tRNAs but not enzyme abundance. A) No
decrease in the levels of the native TRIT1 protein in patient fibroblasts was observed by immunoblotting (using b-actin as a loading control) B) The
isopentenyl modification status of both mitochondrial (mt-) and cytosolic (cy-) tRNAs in patient fibroblasts (lane P) compared to controls (lane C); by
this approach a positive signal is due to lack of isopentenyl modification as detected by an anticodon loop (ACL) probe (the bulky modification on
the N of adenine blocks base pairing with the probe, such that no signal for cy-tRNASer(UGA) with the ACL probe indicates efficient modification in the
control cells [11]); a body probe to a different region of the same tRNA is used as a control for calibration and calculation of steady-state levels. Each
panel shows hybridisation of the same blot with a different probe as indicated to the right. The cytosolic tRNASer(UGA) is poorly modified in patient
fibroblasts (strong ACL probe signal), but tRNASer(UGA) steady-state levels are unchanged. Mt-tRNASer(UCN) is also poorly modified in patient fibroblasts,
although a small pool of mt-tRNASer(UCN) in control fibroblasts lacks the modification. The modification appears to be influential on mt-tRNASer(UCN)
stability, as steady-state levels are decreased by 40% in the patient. The non-substrate mt-tRNACys was probed as a control.
doi:10.1371/journal.pgen.1004424.g004
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The m.7480A.G mutation at position 38 in mt-
tRNASer(UCN) impairs i6A37 modification
As noted in the Introduction, the tRNA substrates of all
characterized isopentenyltransferases have an enzyme recognition
sequence of A36A37A38 in their anticodon loops [11]. Thus we
decided to further investigate a previously reported patient with
mitochondrial myopathy [15] due to a pathogenic (m.7480A.G)
mutation at position 38 in mt-tRNASer(UCN), a substrate of TRIT1
(Figure 6A). The PHA6 assay using a double ACL probe that
matches both the wild type and mutant mt-tRNASer(UCN) (see
Methods) performed on total RNA extracted from homogenised
patient skeletal muscle showed reduced i6A37 modification of mt-
tRNASer(UCN), to,14% of control levels (Figure 6B, quantification
not shown). Furthermore, the steady-state level of mt-tRNASer(-
Figure 5. TRIT1 activity in patient fibroblasts is rescued by transduction with wild-type TRIT1. A) Immunoblotting of the TRIT1 protein in
patient and control fibroblasts after transduction with an empty vector, wild-type TRIT1 (TRIT1-WT) or mutant TRIT1 (TRIT1-Mut) and selection with
puromycin demonstrated overexpression, whilst Ponceau S staining confirmed even loading. B) The PHA6 assay was performed on patient and
control fibroblasts transduced with wild-type TRIT1, mutant TRIT1 or an empty vector, for both mitochondrial (mt-) and cytosolic (ct-) tRNAs serine.
Loading controls are provided by U5 RNA as well as two mitochondrial non-TRIT1 substrates, mt-tRNACys and mt-tRNALeu(UUR). Each sample was run in
duplicate with 3 mg (1X) and 6 mg (2X) of RNA as indicated above the lanes. Transduction of patient fibroblasts with both wild-type and mutant TRIT1
rescued the i6A modification of cytosolic tRNASer(UGA). C) However, only transfection with wild-type TRIT1 was able to efficiently rescue the i6A
modification of mt-tRNASer(UCN). *: p,0.05. D) The steady-state level of cytosolic tRNASer(UGA), calculated using the body probe and the probe to U5
RNA, was found to be increased in all three transduced patient fibroblasts, although this up-regulation was found to be non-specific for cy-
tRNASer(UGA) (data not shown). E) The steady-state level of mt-tRNASer(UCN) was shown to be recovered by transduction with wild-type TRIT1 and to a
lesser extent, mutant TRIT1 (using the body probe and the probes for U5 RNA (black columns) and mt-tRNACys (grey columns)). The error bars indicate
the difference between the duplicate determinations.
doi:10.1371/journal.pgen.1004424.g005
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Figure 6. A mt-tRNASer(UCN) point mutation, m.7480A.G, impairs i6A37 modification. A) The previously reported m.7480A.G mutation
[15] is located at position 38 in the anticodon loop (ACL) of mt-tRNASer(UCN), in the A36A37A38 recognition sequence of TRIT1. B) The i6A modification
of position 37 is decreased (stronger binding of the mt-tRNASer(UCN) double ACL probe) by,86% in patient skeletal muscle relative to control muscle.
Binding of the ACL probe to the non-TRIT1 substrate, mt-tRNACys, confirmed even loading. The steady-state level of mt-tRNASer(UCN) in patient skeletal
muscle is 30% lower than in control muscle (calculated using the two body probes). Both control and patient samples were run in duplicate using
2 mg (1X) and 4 mg (2X) of RNA as indicated above the lanes. C) In vitro isopentylation assay using purified TRIT1, 14C-DMAPP, and synthetic
minihelixes representing the anticodon stem loops (ASLs) of the tRNAs indicated above the lanes. The upper blot is an ethidium bromide-stained gel
of the ASLs after in vitro reaction indicating even loading, whilst the lower blot is the autoradiograph obtained after 3 days of exposure. D) The PHA6
assay was validated and the loss of i6A37 modification in m.7480A.G mutant mt-tRNASer(UCN) confirmed by in vitro modification of synthetic
templates. For reaction samples (R), synthetic RNA minihelixes were in vitro modified using unlabeled-DMAPP and recombinant His-TRIT1. For mock-
treated samples (M), all the components except the His-TRIT1 enzyme were added. After purification, the RNA samples were transferred to a
membrane which was repeatedly hybridized, stripped and rehybridized with 5 different 32P-labeled ASL oligo probes as indicated to the right.
Ethidium bromide staining of the gel confirmed equal loading of each pair of reactions (mock and reaction samples) for each synthetic ACL
interrogated.
doi:10.1371/journal.pgen.1004424.g006
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UCN) was also decreased by ,30% in patient skeletal muscle
compared to control (quantification not shown). Interestingly,
when comparing control skeletal muscle to the previously
described control fibroblasts (Figure 4B), it appears that skeletal
muscle harbours relatively more mt-tRNASer(UCN) lacking the i6A
modification. The in vitromodification assay was also performed on
several synthetic tRNA ASLs, substantiating our finding of a
deficiency in modification activity (Figure 6C). Isopentenyl
modification of wild-type mt-tRNASer(UCN) (lane 3) in vitro is
comparable to that observed for the positive controls,
cy-tRNASec(UCA) (Lane 1) and cy-tRNASer(UGA) (Lane 2). Howev-
er, the m.7480A.G mutation significantly abolishes in vitro activity
of TRIT1 on mt-tRNASer(UCN) (lane 4) to the level observed in the
non-substrates, mt-tRNACys (Lane 5) and mt-tRNALeu(UUR) (Lane
6). Hybridization of ASL probes to synthetic substrates modified in
vitro by DMAPP was observed by the PHA6 assay to be
substantially decreased compared to hybridization of the same
probes to unmodified synthetic substrates (Figure 6D). Hybridiza-
tion of ASL probes to the non-DMAPP substrate mt-tRNACys was
unaffected by treatment with TRIT1. Notably, hybridisation of
ASL probes to mutant mt-tRNASer(UCN) (m.7480A.G) was
unchanged by the DMAPP modification reaction, confirming
the loss of i6A37 modification in the mutant tRNA. These data
validate the PHA6 assay for detection of changes in the i6A
modification status of substrate mitochondrial and cytosolic
tRNAs.
Discussion
Here we describe the investigation of a consanguineous kindred
in which affected children presented with encephalopathy and
myoclonic epilepsy associated with a disorder of mitochondrial
translation. Analysis of whole exome sequencing data indicated
that this was due to a recessively-inherited p.Arg323Gln mutation
in TRIT1, the gene encoding the tRNA isopentenyltransferase
(IPTase) responsible for i6A modification at position 37 in the
anticodon loop of a subset of tRNAs [16], including mt-
tRNASer(UCN), consistent with a previous report on i6A in bovine
mt-tRNASer(UCN) [17].
In addition to the TRIT1 mutation-associated disorder of
mitochondrial dysfunction reported here, we also demonstrated
that a m.7480A.G point mutation of mt-tRNASer(UCN), previ-
ously reported as a cause of progressive mitochondrial myopathy
[15], results in i6A37 hypomodification. In this case, the point
mutation was in the TRIT1 sequence-specific recognition site,
A36A37A38, of mt-tRNASer(UCN). The convergence of two
different mechanisms, one due to a mutation in the TRIT1
enzyme and the other to a mutation in its substrate mt-
tRNASer(UCN), that both cause i6A37 hypomodification of mt-
tRNASer(UCN) and mitochondrial myopathy, provide strong
genetic evidence of the critical importance of i6A37 in mitochon-
drial translation. TRIT1 should therefore be added to the
increasing list of genes encoding mitochondrial tRNA-modifying
enzymes, including MTU1 [18], PUS1 [19], MTO1 [20], MTFMT
[21] and the various mitochondrial aminoacyl-tRNA synthetases
[5], that have been associated with human disease. It is also worth
noting that TRIT1 has been reported as a tumor suppressor and
certain rare variant alleles are associated with poor survival from
lung cancer in some ethnic groups [22,23]; other mitochondrial-
disease associated genes such as GRIM19 have also been
implicated as a tumor suppressor [24]. However, it is not clear
whether this is due to a relationship between cellular respiration
and the mitochondrial function of TRIT1 in the lungs and/or the
enzyme’s cytosolic role. In addition, recent work has demonstrated
an effect of Mod5 in tRNA-gene mediated gene silencing of RNA
polymerase II promoters, suggesting a role for eukaryotic IPTases
beyond their tRNA modification activity [25].
IPTases are conserved in sequence, structure and catalytic
mechanism from bacteria to humans, particularly in the sequence
surrounding the TRIT1 p.Arg323Gln mutation site. Indeed, in all
of the IPTase sequences examined including E. coli MiaA, the
targeted residue is either Arg or Lys. The mod5-i6A37-tRNA
crystal structure shows that this residue comprises one of several
basic side chains that contact the acidic backbone of the tRNA
anticodon stem suggesting that the semi-conservative Arg to Gln
mutation might compromise but not ablate enzyme activity. We
therefore expected that any effect of the p.Arg323Gln mutation on
TRIT1 activity would not be extreme and that the phenotype
would be associated with a moderate decrease in tRNA i6A37
modification. However, to our surprise the mutation severely
impaired the activity of the enzyme in vitro and caused a dramatic
loss of i6A37 from both cy-tRNASer(UGA) and mt-tRNASer(UCN) in
patient fibroblasts. It is important to note that our observation of
i6A37 modification of cy-tRNASer(UGA) contrasts with a previous
study that could not detect this modification in human
cy-tRNASer(UGA) expressed in monkey-derived CV-1 cells [26].
In all eukaryotes examined, the IPTases modify both cytosolic
and mitochondrial tRNAs and mitochondrial localization is a
significant part of the biology. S. cerevisiae employs an intricate
system for maintaining proper distribution of Mod5 to the
mitochondria, nucleus and cytoplasm [27–29]. A prominent
phenotype of S. pombe tit1-D mutants is slow growth on glycerol,
a manifestation of mitochondrial respiratory dysfunction [10]. In
C. elegans, the extended life span phenotype as well as deregulated
development and other phenotypes of gro-1 mutants can be
rescued by the mitochondrial isoform of the GRO-1 IPTase but
not the nuclear and cytoplasmic isoform [30]. It is therefore
noteworthy that while both cytosolic and mitochondrial tRNAs
are lacking i6A37 in patient cells, the manifestations of disease
clearly localize to a mitochondrial cause. Therefore, it may be
important that in addition to hypomodification of mt-tRNASer(-
UCN), the overall levels of the mt-tRNASer(UCN) were significantly
lower in patient fibroblasts. This suggests that in addition to the
,4-fold loss of tRNA specific activity due to lack of i6A37 [10],
mitochondrial translation would be even further compromised by
a decrease in the absolute level of mt-tRNASer(UCN). This may
contribute to a molecular basis for the apparent sensitization of the
mitochondrial-associated phenotype in the patients described here.
Another informative finding was that the TRIT1-mutant could
modify its substrate tRNAs with i6A37 when greatly over-
expressed in the transduced patient fibroblasts. This was not
completely unexpected on the basis of two experimental observa-
tions. As noted above, structure modelling suggested that the
mutation would affect substrate binding but not i6A37 catalytic
activity. Indeed, we observed increased transferase activity with
increased substrate concentration, at least within the technical
limits of the assay (Figures 3B and 3C). Second, the TRIT1
p.Arg323Gln mutant manifested partial activity to complement
the slow growth in glycerol phenotype in the S. pombe tit1-D strain
(Figure 3E). Furthermore, previous studies have shown that this
phenotype remains uncomplemented by a prior characterized tit1-
T12A catalytic mutant that is inactive for i6A37 modification of
tRNA [10,11]. Thus, the partial complementation of this
phenotype (Figure 3E) suggests that the TRIT1 mutant retains
some i6A37 activity, consistent with high activity of the nmt1+
promoter in the multi-copy expression vector.
Recent studies have concluded that although some tRNAs in
human cells contain the A36A37A38 TRIT1 recognition motif
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they accumulate in the i6A37-unmodified form [12]. Somewhat
similarly, the A36A37A38-containing tRNATrp(CCA) in S. cerevisiae
remains unmodified [11]. This further suggests that the subset of
i6A37-containing tRNAs may change under different conditions,
due to varying concentrations of the enzyme or substrate, a




Written informed consent was obtained from the family in
accordance with the Declaration of Helsinki and the study was
approved by the Newcastle and North Tyneside 1 Ethics
Committee.
Histochemical and biochemical analyses
Standard histological and histochemical analyses, including
cytochrome c oxidase (COX), of a skeletal muscle biopsy were
performed according to established protocols [31], on fresh-frozen
skeletal muscle sections (10 mm). Mitochondrial respiratory chain
complex activities were determined in skeletal muscle homoge-
nates as previously described, and expressed relative to the activity
of the matrix marker enzyme, citrate synthase [32].
Molecular genetics
Total DNA was extracted by standard procedures from all
available tissues obtained with consent from familial relatives, and
mtDNA rearrangements were excluded by long-range PCR.
Direct sequencing of the entire mitochondrial genome was
performed on homogenate skeletal muscle DNA.
Genomic DNA from the two affected siblings (II–1 and II–3)
was isolated from blood (DNeasy, Qiagen, Valencia, CA);
fragmented to 150–200 bp with the use of Adaptive Focused
Acoustics (Covaris); end-repaired, adenylated, and ligated to
adapters (Illumina Paired-End Sample Preparation Kit). Ligated
libraries were hybridized with whole-exome baits that covered
27,184 genes (Agilent SureSelect Human All Exon Kit Version 2)
with modifications for the SureSelect Human All Exon Kit
Illumina Paired-end Sequencing Library (Version 2.0.1). Captured
fragments were purified, clonally amplified and sequenced on 2
lanes of an Illumina Genome Analyser IIx using 75 bp paired-end
reads.
The sequence was aligned to the human reference genome
(UCSC hg19) with Burrows Wheeler Aligner (BWA) [33], then
reformatted with the use of SAMtools v0.1.18 [34]. 83.1% of exon
target sequence was covered by .10 reads. Single base variants
were identified with Varscan v2.2 [35] and Indels were identified
with Dindel v1.01 [36]. Variants were annotated using wANNO-
VAR [37]. Lists of on-target variants were filtered against data
from the National Heart, Lung and Blood Institute (NHLBI, NIH,
Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes,
the 1000 Genomes project, and the exome sequences of 315
unrelated in-house control exomes to identify rare homozygous
variants with a Minor allele frequency (MAF) ,0.01.
Variant filtering led to a final list of 40 rare, homozygous,
protein-altering variants of which 4 were mitochondrial according
to the Gene-Ontology database. These genes included TRIT1,
CCDC19, ARSB and SYNJ2 of which TRIT1 segregated with
disease in the family. Targeted resequencing and familial
segregation studies were performed by cycle sequencing using an
ABI 3130xl (Applied Biosystems) system and BigDye Terminator
v3.1 technology. The following primer pairs, including universal
tags, were employed: forward primer, 59-TGTAAAACGAC-
GGCCAGTAGGGAAAATGCACACTGGAG-39, and reverse
primer, 59-CAGGAAACAGCTATGACCTTCCCTTAGGTC-
AGATCCAAAA-39. Analysis of the evolutionary conservation of
the mutated amino acid across a range of homologous proteins
was performed by the freely available Clustal Omega multiple
sequence alignment software (http://www.ebi.ac.uk/Tools/msa/
clustalo/) [38].
Culture of primary fibroblasts
Primary human fibroblast cell lines were established from the
patient as well as from controls according to standard protocols
and cultured at 37uC, in a humidified, 5% CO2 atmosphere.
Fibroblasts were maintained as monolayers in Minimum Essential
Media (MEM) (Life Technologies #21090) supplemented with
FBS to 10%, 1x MEM-vitamins, 21 mM L-Glutamine, 1 mM
sodium pyruvate, 1x penicillin/streptomycin, 1x non-essential
amino acids, and 0.41 mM uridine.
Fibroblast transduction
TRIT1 wild-type and p.Arg323Gln mutant open reading
frames were cloned into the pOP retroviral vector (Radichev et
al., 2006) in frame with FLAG and HA epitope tags at the 59 end
using the XhoI and NotI sites, and sequencing was performed for
confirmation. The preparation of the retroviral supernatants and
the transduction of the control and patient fibroblasts were done as
described [39].
Micro-scale oxygraphy analysis of live cells
Live cell respiration studies were performed by micro-scale
oxygraphy using the Seahorse XFe Extracellular Flux Analyzer 24
(Seahorse Bioscience) according to manufacturer’s instructions.
Fibroblasts were seeded at a density of 30,000 cells/well.
Mitochondrial function was assayed through the sequential
addition of oligomycin (to 1.3 mM) to block the ATP synthase, 2
additions of carbonyl cyanide 4-(trifluoromethoxy)-phenylhydra-
zone (FCCP), a respiratory uncoupler which drives maximal
respiration (to 2 mM and then to 3 mM), and antimycin (to
2.5 mM) to inhibit Complex III.
Oxygen consumption rate (OCR) and proton production rate
(PPR) measurements for each well were normalized by cell
number. Non-mitochondrial respiration was subtracted from all
OCR values prior to analysis; spare respiratory capacity (SRC)
equals maximal OCR - basal OCR, ATP coupling efficiency
equals (basal OCR - oligomycin-inhibited OCR)/(basal
OCR*100). Seven separate control cell lines underwent multiple
testing and the means were combined to calculate control data
(mean 6 SD; n= 7). Patient fibroblasts were tested multiple times
(n = 21). An unpaired, two-tailed Student’s t-test was performed to
determine the significance of differences between the data sets and
P-values were considered significant at the 95% confidence
interval.
SDS-PAGE and immunoblotting
Total cellular protein was extracted from patient and control
fibroblasts (as well as transfected cell lines), size separated on a
10% separating gel by SDS-PAGE and transferred to a methanol-
activated PVDF membrane. Immunoblotting was performed using
primary antibodies to NDUFA9, NDUFB8, NDUFA13, SDHA,
UQCRC2, MTCOI, MTCOII, COXIV and ATPB (all from
Abcam), TRIT1 (GeneTex GTX120508) and b-actin (Sigma
A5316) as a loading control and TOMM20 (Abcam) as a
non-respiratory chain protein mitochondrial control. Chemilumi-
nescent detection of the bands was achieved using the Amersham
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ECL Prime Kit (GE Healthcare) for signal development, following
manufacturer’s instructions and the membrane was viewed using
the ChemiDocTMMP Imaging System (Bio-Rad).
Mitochondrial preparation and subfractionation
Subcellular fractions were prepared as described previously
[40]. The same amount of protein (40 mg) from whole cell lysate,
post-mitochondrial supernatant and mitochondrial subfractions
was loaded onto a 12% SDS-PAGE gel, transferred to a PVDF
membrane and analysed by immunoblotting using primary
antibodies to TOMM20 (Santa Cruz), AIF (NEB), GDH (custom
made against mature recombinant protein), NDUFA9 (Mitos-
ciences), eIF4E (Cell Signaling). Chemiluminescent detection of
the bands was achieved as described before.
Metabolic labelling of in vitro mitochondrial translation
The translation of proteins encoded by the mtDNA in patient
fibroblasts was assessed by labelling with 35S-methionine/35S-
cysteine (Perkin Elmer) as described previously [41]. Cytosolic
translation was inhibited by co-incubation of the radioisotopes
with 100 mg/ml emetine dihydrochloride. Total cell protein was
extracted from both control and patient fibroblasts and 50 mg
loaded onto a 15%–20% gradient gel for SDS-PAGE. Assessment
of protein loading was achieved by Coomassie blue staining, and
the gel was visualised by exposure to a blank PhosphorImager
screen that was imaged using a Typhoon system (GE Healthcare).
In vitro modification assay
The in vitro modification activity of both wild-type and mutant
TRIT1 was determined as previously described [11] using
recombinantly-expressed enzyme from E. coli recovered using a
Histidine tag [42]. Synthetic RNA minihelixes representing the
target anticodon stem/loop (ASL) sequences of various tRNAs
were used as templates for modification with 14C-labelled
dimethylallyl pyrophosphate (DMAPP). In this assay, the iso-
pentenyl group of DMAPP is transferred to A37 in substrate
tRNAs by the IPTase TRIT1. The following RNA oligos were
designed with an additional G-C base pair added to each ASL to









Decreased hybridization efficiency of complimentary DNA
oligos due to the incorporation of the isopentenyl group in
synthetic RNA minihelixes was confirmed by running an in vitro
modification reaction with unlabeled DMAPP and recombinant
His-TRIT1. We used the same protocol for the in vitro
modification reaction as described previously [11], replacing
14C-labeled DMAPP with unlabeled DMAPP (100 nmol). For
each sample, two reactions were performed. In mock-treated
samples, all the components of the in vitro reaction were added
except His-TRIT1. After the reaction, the RNA sample was
purified by a phenol-chloroform extraction and loaded on a 15%
TBE-Urea gel. The RNA was transferred to a GeneScreen Plus
Hybridization Transfer Membrane (Perkin Elmer, catalog #
NEF986001PK) and hybridized with 32P-labeled anticodon loop
(ACL) oligos as described in the legend of Figure 6D. The
sequences of DNA oligos used for this experiment are the same as
used elsewhere in this paper.
The PHA6 tRNA-i6A37 detection assay
Total RNA isolation from skeletal muscle and human primary
cell lines was performed using TRIzol according to manufacturer’s
protocol. The impact of the TRIT1 mutation on in vivo levels of
the i6A37 modification in both cytosolic and mitochondrial tRNAs
was assessed by the Positive Hybridisation in the Absence of i6A
(PHA6) assay, which is an adaptation of high-resolution northern
analysis [11]. The following anticodon loop (ACL) and body (BP)
probes were used (all written as 59-39): mt-tRNACys ACL,
TCTTCGAATTTGCAATTCAATATG and BP, AGCCCC-
GGCAGGTTTGAAGCT, cy-tRNASer(UGA) ACL, CCCATTG-
GATTT CAAGTCCAACGC, and BP, GCAGGATTCGAACC-
TGCGCGGG, wild-type mt-tRNASer(UCN) ACL, CAAAGCTG-
GTTTCAAGCCAACCCC (used for analysis of the patient
carrying the TRIT1 mutation), mutant mt-tRNASer(UCN) ACL,
CAAAGCTGGCTTCAAGCCAACCCC (both the wild-type and
mutation-bearing probes were used together as a ‘double ACL
probe’; the complement of the mutated base is underlined) and mt-
tRNASer(UCN) BP, AAGGAAGGAATCGAACCCCCC, mt-
tRNALeu(UUR) BP, GTTAAGAAGAGG AATTGAACCTC and
U5 probe, TCCTCTCCACGGAAATCTTTA.
Phenotype rescue analyses in S. pombe
The wild-type TRIT1 or mutant TRIT1 was cloned into the
pREP82X plasmid under the nmt1+ promoter before transfor-
mation into a yNB5 (tit1-D) strain of S. pombe. The experiments
related to tRNA-mediated anti-suppression and growth defi-
ciency in glycerol were performed as described previously
[10,11].
Phenotype rescue analyses in S. cerevisiae
The S. cerevisiae yeast strain used was BY4742 mod5-D (MATa
his3D1 leu2D0 lys2D0 ura3D0 mod5::KanMX4) from the Euroscarf
collection. The MOD5 gene was PCR-amplified with Kod HiFi
Polymerase using primers MOD5CFw (gactagaaaatcgatgtgtcagg)
and MOD5CSalIRv (ccgccGTCGACgcttgtcat cctccctttcc), di-
gested with KpnI and SalI and cloned in the centromeric vector,
pFL38 [43], thus obtaining the plasmid pFL38MOD5. The
mod5K294R humanized and mod5K294Q mutant alleles were
obtained by site-directed mutagenesis as described previously
[44], on a MOD5 gene fragment obtained through amplification
with the upstream forward primer MOD5MUTFw (ggagcccctg-
cagcttcatg) and the reverse mutagenic primer MOD5hK294RFw
(cgagaacacgtcaatacgcaCGCaggcaggtaaaatggatcaag) or MOD5K2
94QFw (cgagaacacgtc aatacgcaCaaaggcaggtaaaatggatcaag). The
amplified fragments were digested with BamHI and SalI and
subcloned in BamHI-SalI-digested pFL38MOD5.
Plasmids were introduced in a BY4742 mod5D strain
according to [45]. Growth assays were performed at 28uC in
SD medium (0.69% YNB (Formedium, Norfolk, UK), without
amino acids for which the strain is auxotroph) supplemented
with 2% glucose (w/v) or 2% ethanol (v/v). Images of the
colonies in the spots were acquired at 40X magnification with
a Zenith inverted microscope through an Optikam 3 Digital
Camera (Optika).
Oxygen consumption rate was measured at 30uC from
suspensions of yeast cells cultured for 24 hours at 28uC in SD
medium supplemented with glucose at a non-repressing concen-
tration of 0.6% using a Clark-type oxygen electrode (Oxygraph
System Hansatech Instruments England) with 1 ml of air-
saturated respiration buffer (0.1 M phthalate – KOH, pH 5.0),
0.5% glucose. The reaction was started by addition of 20 mg of
wet-weight cells.
Defective i6a Modification of tRNAs Causes Disease
PLOS Genetics | www.plosgenetics.org 12 June 2014 | Volume 10 | Issue 6 | e1004424
Supporting Information
Figure S1 MOD5-D S. cerevisiae exhibit a mild respiratory defect
that is not rescueable with mutant Mod5K294Q. A) A budding yeast
Saccharomyces cerevisiae strain, mod5-D, was transformed with wild-
type MOD5, an empty vector, a ‘‘humanized’’ mod5K294R allele or
the mutant mod5K294Q allele. Calculation of the doubling times
(mins) for each yeast strain grown on glucose (black columns) or
ethanol (grey columns) confirmed an oxidative growth defect in
mod5-D yeast transformed with an empty vector or a mutant
mod5K294Q allele but normal growth in mod5-D yeast transformed
with a humanized mod5K294R allele. *: p,0.05;**,0.01 (unpaired
two-tailed t-test). B) Respiratory rates were normalized to the
strain transformed with wild-typeMOD5, for which the respiratory
rate was 103 nmol.min21.mg21. The mod5-D yeast transformed
with a ‘humanized’ mod5K294R allele showed normal respiration,
whilst mod5-D yeast transformed with an empty vector or a mutant
mod5K294Q allele had significantly reduced respiration rates. Values
are the mean of three independent experiments, each with an
independent clone. *: p,0.05;**,0.01:***: p,0.001 (paired two-
tailed t- test). The error bars displayed on each graph indicate
standard deviation.
(TIF)
Table S1 mtDNA sequencing data. Whole mtDNA sequencing
of the proband (II-3) identified a number of known polymorphisms
but no candidate pathogenic mutations (based upon the MitoMap
(http://www.mitomap.org/MITOMAP) and mtDB (http://www.
mtdb.igp.uu.se/) databases as well as our in-house database of .
950 human mtDNA sequences). The non-coding region refers to
the D-loop region of mtDNA, which is highly polymorphic and
encodes no genes; the coding region refers to each of the 13
protein-encoding genes, 22 mt-tRNA genes and 2 mt-rRNA genes.
(DOCX)
Table S2 Variant numbers from in-house bioinformatic
pipeline. On-target: Chromosome and position of variants
matches within exome capture target coordinates +/2 500bp.
Rare: Variant has a Minor Allele Frequency (MAF) less than
0.01 in the 1000 genomes, NHLBI-6500-ESP or 315 In-
House exome databases. Protein Altering: Annovar predicts
variant is ‘exonic’ or ‘splicing’, but excluding ‘synonymous’.
Shared Homozygous: Variant genotype is homozygous (V/V)
in one or both patient, allowing for non-coverage (0) in one
patient. Mitochondrial (GO-terms): Gene containing variant
is listed with the search term ‘mitoch*’ in the Gene-Ontology
database. Mitochondrial (‘Original’ gene-list): Gene contain-
ing variant is listed as being ‘mitochondrial’ on Mootha gene
list.
(DOCX)
Text S1 Clinical summary. A detailed report of the proband’s
clinical presentation and disease course is provided along with
clinical information about his affected sister.
(DOCX)
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